. 2017 Jun 20;24(8):427–443. doi: 10.1530/ERC-17-0196
This work is licensed under a Table 1.
Summary of clinical data comparing hereditary and sporadic patients.
| Patients | Hereditary (n = 26) | Sporadic (n = 215) |
|---|---|---|
| WHO grade 1a | 10 | 115 |
| WHO grade 2a | 8 | 45 |
| Unknown tumor grade | 8 | 55 |
| TxNxM0b | 5 | 61 |
| TxNxM1b | 20 | 147 |
| Unknown tumor stage | 1 | 7 |
| Dead with disease | 13 | 111 |
| Alive with disease | 11 | 96 |
| No follow-up information | 2 | 8 |
| Median age at diagnosis | 57 (34–68) | 61 (23–90) |
| Median survival (months) | 83 (40–348) | 92.5 (2–348) |
a
Rindi G, Arnold R, Bosman FT. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND et al., editors. WHO classification of tumors of the digestive system. Lyon: IARC, 2010; bTumors classified according to: Rindi G, Kloppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006, 449:395–401.